A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Condition:   Head and Neck Cancer
Interventions:   Drug: Azacitidine;   Drug: Durvalumab;   Drug: Tremelimumab
Sponsors:   Massachusetts General Hospital;   AstraZeneca
Not yet recruiting - verified January 2017

http://ift.tt/2jnoJwZ